Compare INBK & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | INBK | NKTX |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | United States | United States |
| Employees | 355 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 179.3M | 188.9M |
| IPO Year | N/A | 2020 |
| Metric | INBK | NKTX |
|---|---|---|
| Price | $23.92 | $3.04 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $23.25 | $11.33 |
| AVG Volume (30 Days) | 56.1K | ★ 749.2K |
| Earning Date | 04-30-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.06% | N/A |
| EPS Growth | N/A | ★ 11.88 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $279.34 | N/A |
| Revenue Next Year | $12.97 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.05 | $1.63 |
| 52 Week High | $28.51 | $3.65 |
| Indicator | INBK | NKTX |
|---|---|---|
| Relative Strength Index (RSI) | 50.19 | 55.80 |
| Support Level | $23.26 | $1.88 |
| Resistance Level | $24.85 | $3.35 |
| Average True Range (ATR) | 0.79 | 0.22 |
| MACD | -0.17 | -0.03 |
| Stochastic Oscillator | 24.68 | 59.33 |
First Internet Bancorp is a bank holding company. Through its subsidiaries, it provides commercial real estate (CRE) lending, including nationwide single tenant lease financing and commercial and industrial (C&I) lending, including business banking or treasury management services. The company offers its products and services through the internet and does not have any branches. With operations organized into a single segment called the Commercial Banking segment, it also provides retail banking services.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK-cell expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.